MedPacto KRX:235980KOSDAQ

메드팩토 · Korean news coverage and regulatory filings, organized.

Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked28since Sep 11

In Q2 2026, MedPacto reported revenue of ₩1.0bn, up 25.0% year on year, and an operating loss of ₩3.6bn. MedPacto (메드팩토) appeared in 0 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 19 with 5 articles. The most common catalyst was clinical & approvals (3).

Filing signals Clinical trial filing 4 quarters of losses Screener

MedPacto quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩1.0bn+25.0%−₩3.6bn−₩3.2bn
Q1 2026₩1.3bn+206.2%−₩4.2bn−₩3.8bn
Q4 2025 derived₩1.4bn–−₩2.9bn
margin −204.4%
−₩2.7bn
Q3 2025₩1.2bn–−₩4.7bn−₩4.5bn
Q2 2025₩840m–−₩2.6bn−₩2.3bn
Q1 2025₩430m–−₩3.8bn−₩3.4bn
Q4 2024 derived₩0m–−₩4.8bn−₩4.4bn
Q3 2024₩0m–−₩2.2bn−₩1.8bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

MedPacto top stories 2 weeks, by number of outlets

  1. 1
    메드팩토, 백토서팁 골육종 2상 중용량 추가…美 FDA 승인
    2 outlets · 3 articlesFirst report Oct 19 11:40 이데일리Regulatory approval
  2. 2
  3. 3
    [HIT알공] 메드팩토, 용량비교 위해 골육종 美 1/2상 변경승인받아
    1 outlets · 1 articlesFirst report Oct 19 18:10 히트뉴스
  4. 4

Latest MedPacto news Korean headlines